Research programme: influenza virus vaccine - KAEL-GemVax

Drug Profile

Research programme: influenza virus vaccine - KAEL-GemVax

Alternative Names: EP 1400; EP 1450

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmexa-Epimmune
  • Developer GemVax & KAEL; Ichor Medical Systems
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Influenza virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in USA (IM)
  • 28 May 2009 Pharmexa Epimmune has been acquired and merged into VaxOnco
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top